IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes. In Vitro IRES-C11 blocks cyclin D1 IRES-dependent initiation and demonstrates synergistic anti-glioblastoma properties when combined with the mechanistic target of mTOR PP242. IRES-C11 (50 nM) significantly inhibits both cyclin D1 and c-MYC IRES activity. IRES-C11 treatment induces a significant shift in both cyclin D1 and c-MYC mRNA to monosomal/nonribosomal fractions, whereas actin mRNA distribution is unaffected. IRES-C11 inhibits both cyclin D1 and c-MYC IRES-mediated mRNA translation, leading to reductions in protein levels. Mechanistic studies with IRES-C11 reveal binding of the inhibitors within the UP1 fragment of heterogeneous nuclear ribonucleoprotein A1. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid